BPL’s leadership team has been built up with an emphasis on industry expertise across the life science and pharmaceutical sectors, supported by the team’s broad experience working for leading international companies.
The team believes in energising all employees across every level of the organisation and driving close collaboration between the company’s production, technology and R&D disciplines to deliver long-term strategic growth and support the future success of the business.
David Gao was appointed CEO and Vice Chairman of BPL Holdings in December 2018. David brings 15 years of experience in the healthcare industry. Prior to joining BPL, he was CEO and Chairman of China Biologics (2012 to 2018) and BMP Sunstone Corporation (2004 to 2011), both of which were publicly traded in the NASDAQ stock exchange. He has a long leadership experience in multinational management roles in both the United States and China. David received a degree in Engineering from the University of Hannover and an MBA from Sloan School of Management, MIT.
Michael Mensa joined BPL in 2015 and was appointed CFO in May 2017 and President and BPL Board member in November 2019. Previously, Michael spent 19 years at GE in various global senior finance roles, mainly in the Energy and Industrials businesses, as well lead roles in M&A and integration processes. His latest role prior to joining BPL was that of CFO for GE’s Software Solutions business. Michael has a dual bachelor’s degree for Finance and Economics from Boston College.
Evan Selig joined BPL in January 2020 after 10 years at VIIV Healthcare, a joint venture of GSK, Pfizer and Shionogi, where he helped the company to develop, launch and grow four new medicines and to implement its legal and compliance framework across functions for its global business. Prior to this, Evan worked at GSK for 4 years supporting the US pharmaceuticals and vaccines businesses with legal matters relating to pricing, contracting, sales and marketing. He spent 6 years as an associate at Reed Smith LLP advising life sciences and health care companies on mergers & acquisitions and strategic commercial and R&D transactions.
Richard Gray joined BPL in 2016, initially as Engineering Director, he was subsequently promoted to Chief Operating Officer in 2019. Richard holds responsibility for all Manufacturing functions, Quality and New Product Development. Richard brings 18 years of experience within Pharmaceuticals and 30 years of experience within manufacturing. He has previously worked for a number of multinational companies including Pfizer, Wyeth, Emerson, Huntsman and ICI. He holds an MBA from Manchester Business School and an Honours Degree in Engineering.
With over 25 years of progressive industry experience Bob has continually demonstrated a passion for building customer focused teams, strong employee engagement and delivering results. Bob has a proven track record of working successfully in commercial leadership roles including commercial operations, sales, marketing and training functions. He deeply understands the evolving healthcare landscape across customer types, business models and therapeutic areas around the globe. Bob joined BPL in 2015, to help build the US organisation and lead the commercial sales team. In his current role, Bob is the US President and Chief Commercial Officer for BPL’s Global Business.
Marvin Dyke joined BPL in October 2016 to lead BPL Plasma’s Operational Excellence and New Center Development initiatives. Marvin was appointed Head of Quality in July 2018 and President in March 2019. Previously, Marvin worked at Thermo Fisher Scientific for 13 years, serving in finance, manufacturing, and general management roles within their Analytical Instruments and BioPharma Services divisions.